Knight Therapeutics Inc.
GUD.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 77.59M | 61.37M | 69.20M | 67.65M | 69.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 77.59M | 61.37M | 69.20M | 67.65M | 69.84M |
| Cost of Revenue | 45.19M | 37.08M | 40.37M | 34.64M | 35.25M |
| Gross Profit | 32.40M | 24.29M | 28.83M | 33.01M | 34.59M |
| SG&A Expenses | 22.76M | 18.22M | 18.09M | 18.68M | 18.54M |
| Depreciation & Amortization | 7.76M | 6.60M | 7.59M | 8.20M | 8.53M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.25M | 65.23M | 71.31M | 65.30M | 66.56M |
| Operating Income | -2.65M | -3.86M | -2.11M | 2.35M | 3.28M |
| Income Before Tax | -11.28M | -278.00K | 5.63M | 445.80K | 521.10K |
| Income Tax Expenses | -2.16M | -1.80M | -2.04M | 383.50K | 1.94M |
| Earnings from Continuing Operations | -9.12M | 1.52M | 7.67M | 62.30K | -1.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.12M | 1.52M | 7.67M | 62.30K | -1.42M |
| EBIT | -2.65M | -3.86M | -2.11M | 2.35M | 3.28M |
| EBITDA | 6.12M | 4.21M | 4.62M | 12.17M | 12.91M |
| EPS Basic | -0.09 | 0.02 | 0.08 | 0.00 | -0.01 |
| Normalized Basic EPS | -0.05 | 0.00 | 0.08 | 0.00 | 0.00 |
| EPS Diluted | -0.09 | 0.01 | 0.07 | 0.00 | -0.01 |
| Normalized Diluted EPS | -0.05 | 0.00 | 0.08 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 99.63M | 99.64M | 100.53M | 101.13M | 101.33M |
| Average Diluted Shares Outstanding | 99.63M | 100.08M | 100.94M | 101.13M | 101.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |